<p>2025 年 12 月 02 日- 上午 08:50</p>
<p><strong>任命进一步增强了临床和转化深度，Ernexa 将其一流的 iMSC 细胞治疗平台推进至首次人体试验</strong></p>
<p>马萨诸塞州剑桥，2025 年 12 月 02 日（GLOBE NEWSWIRE）-- Ernexa Therapeutics（纳斯达克：ERNA），一家开发用于治疗晚期癌症和自身免疫疾病的新型细胞疗法的行业创新者，今天宣布任命 Ira S. Winer 博士，医学博士，哲学博士，FACOG，加入其科学和医学顾问委员会。</p>
<p>Winer 博士是一位全国知名的妇科肿瘤学家和转化科学家。他在女性肿瘤学、免疫治疗和早期临床开发方面的专业知识进一步增强了 Ernexa 的能力，推动其专有的诱导性间充质干细胞（iMSC）平台及其主导项目 ERNA-101 朝着关键里程碑迈进，包括首次人体试验。</p>
<p>“我们很高兴欢迎 Winer 博士加入我们的顾问委员会，” Ernexa Therapeutics 的总裁兼首席执行官 Sanjeev Luther 表示。“他在女性肿瘤学方面深厚的临床和转化经验直接支持了我们推进晚期癌症和自身免疫疾病治疗的使命。当我们在卵巢癌方面推进 ERNA-101 并将我们的管道扩展到炎症和自身免疫指征时，Winer 博士的战略指导将帮助我们将创新转化为有意义的临床结果。”</p>
<p>Winer 博士补充道：“我很荣幸在如此关键的时刻加入 Ernexa Therapeutics 的顾问委员会。Ernexa 专注于将诱导性多能干细胞（iPSCs）工程化为同种异体 iMSCs 作为现成疗法，体现了科学创新和对患者的深切承诺。我期待着贡献我的转化和临床科学经验，帮助指导 Ernexa 从有前景的创新走向有意义的患者结果。”</p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/Resource/Download/de652864-7d39-4b89-873f-72a4b65d76be/dr-ira-s-winer-m-d-ph-d-facog.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/Resource/Download/de652864-7d39-4b89-873f-72a4b65d76be/dr-ira-s-winer-m-d-ph-d-facog.png"/></p>
<p>Winer 博士在韦恩州立大学医学院肿瘤学系担任教授（临床教育者），并在巴巴拉·安·卡曼诺斯癌症研究所担任杰出的妇科肿瘤学家和外科肿瘤学家。在卡曼诺斯，Winer 博士因其外科技能和在早期临床试验中的领导能力而广受认可，为患者提供卵巢癌、子宫内膜癌、宫颈癌、输卵管癌和外阴癌的前沿治疗。</p>
<p>除了他的临床实践外，他还拥有细胞和分子生物学的博士学位，使他的妇科癌症研究基于科学创新和转化研究。Winer 博士广泛发表论文，并积极参与专业学会，他的工作重点是卵巢癌、子宫癌、宫颈癌和外阴癌，特别强调免疫治疗、分子靶向治疗以及连接实验室科学与患者护理的转化研究。</p>
<p><strong>关于 Ernexa Therapeutics</strong></p>
<p>Ernexa Therapeutics（纳斯达克：ERNA）正在开发用于治疗晚期癌症和自身免疫疾病的创新细胞疗法。Ernexa 的核心技术专注于将诱导性多能干细胞（iPSCs）工程化并转化为诱导性间充质干细胞（iMSCs）。Ernexa 的同种异体合成 iMSCs 提供了一种可扩展的现成治疗解决方案，无需患者特定的细胞采集。</p>
<p>ERNA-101 是该公司的主导细胞治疗产品，旨在激活和调节免疫系统对癌细胞的识别和攻击。ERNA-201 是一个旨在针对炎症和治疗自身免疫疾病的细胞治疗产品。该公司的初步重点是开发 ERNA-101 用于治疗卵巢癌。</p>
<p>欲了解更多信息，请访问 www.ernexatx.com。</p>
<p><strong>媒体联系</strong></p>
<p>Sharon Golubchik</p>
<p>RAYNZ</p>
<p>sharon@raynzhealth.com</p>
<p><strong>投资者联系</strong></p>
<p>Jenene Thomas</p>
<p>JTC Team, LLC</p>
<p>(908) 824-0775</p>
<p>ENRA@jtcir.com</p>
<p>与此公告相关的照片可在 https://www.globenewswire.com/NewsRoom/AttachmentNg/de652864-7d39-4b89-873f-72a4b65d76be 获取</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVNU5EZzFNaU0zTXpBd05UQXdJekl5TVRBeU9EQT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVNU5EZzFNaU0zTXpBd05UQXdJekl5TVRBeU9EQT0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NTc5MGVkZjktOGQ1Yi00YzQwLWJhZGQtYzAzYWVlYzJmYWRhLTEyMjE4MzMtMjAyNS0xMi0wMi1lbg==/tiny/Ernexa-Therapeutics-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NTc5MGVkZjktOGQ1Yi00YzQwLWJhZGQtYzAzYWVlYzJmYWRhLTEyMjE4MzMtMjAyNS0xMi0wMi1lbg==/tiny/Ernexa-Therapeutics-Inc-.png"/></p>

ERNA

<p>Ernexa Therapeutics 已任命领先的肿瘤学家 Ira S. Winer 博士为其科学与医学顾问委员会成员。此举旨在增强 Ernexa 在推进其 iMSC 细胞治疗平台进入首次人体试验中的临床和转化能力。Winer 博士在女性肿瘤学和免疫治疗方面的专业知识将支持 Ernexa 开发针对晚期癌症和自身免疫疾病的治疗，特别是聚焦于卵巢癌</p>

<p>12/02/2025 - 08:50 AM</p>
<div class="lb-trans"><p>2025 年 12 月 02 日- 上午 08:50</p>
</div><p><strong>Appointment reinforces clinical and translational depth as Ernexa advances its best-in-class iMSC cell therapy platform into first-in-human trials</strong></p>
<div class="lb-trans"><p><strong>任命进一步增强了临床和转化深度，Ernexa 将其一流的 iMSC 细胞治疗平台推进至首次人体试验</strong></p>
</div><p>CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the appointment of Dr. Ira S. Winer, M.D., Ph.D., FACOG, to its Scientific and Medical Advisory Board.</p>
<div class="lb-trans"><p>马萨诸塞州剑桥，2025 年 12 月 02 日（GLOBE NEWSWIRE）-- Ernexa Therapeutics（纳斯达克：ERNA），一家开发用于治疗晚期癌症和自身免疫疾病的新型细胞疗法的行业创新者，今天宣布任命 Ira S. Winer 博士，医学博士，哲学博士，FACOG，加入其科学和医学顾问委员会。</p>
</div><p>Dr. Winer is a nationally recognized gynecologic oncologist and translational scientist. His expertise in women’s oncology, immunotherapy, and early-phase clinical development further strengthens Ernexa’s capabilities as it advances its proprietary induced mesenchymal stem cells (iMSC) platform and lead program, ERNA-101, toward key milestones, including first-in-human trials.</p>
<div class="lb-trans"><p>Winer 博士是一位全国知名的妇科肿瘤学家和转化科学家。他在女性肿瘤学、免疫治疗和早期临床开发方面的专业知识进一步增强了 Ernexa 的能力，推动其专有的诱导性间充质干细胞（iMSC）平台及其主导项目 ERNA-101 朝着关键里程碑迈进，包括首次人体试验。</p>
</div><p>“We are delighted to welcome Dr. Winer to our Advisory Board,” said Sanjeev Luther, President and CEO of Ernexa Therapeutics. “His deep clinical and translational experience in women’s oncology directly supports our mission to advance treatments for advanced cancer and autoimmune disease. As we move ERNA-101 forward in ovarian cancer and expand our pipeline into inflammatory and autoimmune indications, Dr. Winer’s strategic guidance will help us translate innovation into meaningful clinical outcomes.”</p>
<div class="lb-trans"><p>“我们很高兴欢迎 Winer 博士加入我们的顾问委员会，” Ernexa Therapeutics 的总裁兼首席执行官 Sanjeev Luther 表示。“他在女性肿瘤学方面深厚的临床和转化经验直接支持了我们推进晚期癌症和自身免疫疾病治疗的使命。当我们在卵巢癌方面推进 ERNA-101 并将我们的管道扩展到炎症和自身免疫指征时，Winer 博士的战略指导将帮助我们将创新转化为有意义的临床结果。”</p>
</div><p>Dr. Winer added, “I am honored to join the Advisory Board of Ernexa Therapeutics at such a pivotal moment. Ernexa’s focus on engineering induced pluripotent stem cells (iPSCs) into allogeneic iMSCs as off-the-shelf therapies reflects both scientific innovation and a deep commitment to patients. I look forward to contributing my experience in translational and clinical science to help guide Ernexa’s path from promising innovation to meaningful patient outcomes.”</p>
<div class="lb-trans"><p>Winer 博士补充道：“我很荣幸在如此关键的时刻加入 Ernexa Therapeutics 的顾问委员会。Ernexa 专注于将诱导性多能干细胞（iPSCs）工程化为同种异体 iMSCs 作为现成疗法，体现了科学创新和对患者的深切承诺。我期待着贡献我的转化和临床科学经验，帮助指导 Ernexa 从有前景的创新走向有意义的患者结果。”</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/Resource/Download/de652864-7d39-4b89-873f-72a4b65d76be/dr-ira-s-winer-m-d-ph-d-facog.png" alt="" original-src="https://ml.globenewswire.com/Resource/Download/de652864-7d39-4b89-873f-72a4b65d76be/dr-ira-s-winer-m-d-ph-d-facog.png"/></p>
<p>Dr. Winer serves as a Professor (Clinician Educator) in the Department of Oncology at Wayne State University School of Medicine, and as a distinguished gynecologic oncologist and surgical oncologist at the Barbara Ann Karmanos Cancer Institute. At Karmanos, Dr. Winer is widely recognized for his surgical skill and leadership in early-phase clinical trials, offering patients access to cutting-edge therapies in ovarian, endometrial, cervical, fallopian tube, and vulvar cancers.</p>
<div class="lb-trans"><p>Winer 博士在韦恩州立大学医学院肿瘤学系担任教授（临床教育者），并在巴巴拉·安·卡曼诺斯癌症研究所担任杰出的妇科肿瘤学家和外科肿瘤学家。在卡曼诺斯，Winer 博士因其外科技能和在早期临床试验中的领导能力而广受认可，为患者提供卵巢癌、子宫内膜癌、宫颈癌、输卵管癌和外阴癌的前沿治疗。</p>
</div><p>In addition to his clinical practice, he holds a Ph.D. in cellular and molecular biology, grounding his approach to gynecologic cancers in scientific innovation and translational research. Widely published and an active member of professional societies, Dr. Winer’s work focuses on ovarian, uterine, cervical, and vulvar cancers, with a particular emphasis on immunotherapy, molecularly targeted treatments, and translational research that bridges laboratory science and patient care.</p>
<div class="lb-trans"><p>除了他的临床实践外，他还拥有细胞和分子生物学的博士学位，使他的妇科癌症研究基于科学创新和转化研究。Winer 博士广泛发表论文，并积极参与专业学会，他的工作重点是卵巢癌、子宫癌、宫颈癌和外阴癌，特别强调免疫治疗、分子靶向治疗以及连接实验室科学与患者护理的转化研究。</p>
</div><p><strong>About Ernexa Therapeutics</strong></p>
<div class="lb-trans"><p><strong>关于 Ernexa Therapeutics</strong></p>
</div><p>Ernexa Therapeutics (NASDAQ: ERNA) is developing innovative cell therapies for the treatment of advanced cancer and autoimmune diseases. Ernexa’s core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexa’s allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment solution, without needing patient-specific cell harvesting.</p>
<div class="lb-trans"><p>Ernexa Therapeutics（纳斯达克：ERNA）正在开发用于治疗晚期癌症和自身免疫疾病的创新细胞疗法。Ernexa 的核心技术专注于将诱导性多能干细胞（iPSCs）工程化并转化为诱导性间充质干细胞（iMSCs）。Ernexa 的同种异体合成 iMSCs 提供了一种可扩展的现成治疗解决方案，无需患者特定的细胞采集。</p>
</div><p>ERNA-101 is the company’s lead cell therapy product, designed to activate and regulate the immune system's response to recognize and attack cancer cells. ERNA-201 is a cell therapy product designed to target inflammation and treat autoimmune disease. The company’s initial focus is to develop ERNA-101 for the treatment of ovarian cancer.</p>
<div class="lb-trans"><p>ERNA-101 是该公司的主导细胞治疗产品，旨在激活和调节免疫系统对癌细胞的识别和攻击。ERNA-201 是一个旨在针对炎症和治疗自身免疫疾病的细胞治疗产品。该公司的初步重点是开发 ERNA-101 用于治疗卵巢癌。</p>
</div><p>For more information, visit www.ernexatx.com.</p>
<div class="lb-trans"><p>欲了解更多信息，请访问 www.ernexatx.com。</p>
</div><p><strong>Media Contact</strong></p>
<div class="lb-trans"><p><strong>媒体联系</strong></p>
</div><p>Sharon Golubchik</p>
<div class="lb-trans"><p>Sharon Golubchik</p>
</div><p>RAYNZ</p>
<div class="lb-trans"><p>RAYNZ</p>
</div><p>sharon@raynzhealth.com</p>
<div class="lb-trans"><p>sharon@raynzhealth.com</p>
</div><p><strong>Investor Contact</strong></p>
<div class="lb-trans"><p><strong>投资者联系</strong></p>
</div><p>Jenene Thomas</p>
<div class="lb-trans"><p>Jenene Thomas</p>
</div><p>JTC Team, LLC</p>
<div class="lb-trans"><p>JTC Team, LLC</p>
</div><p>(908) 824-0775</p>
<div class="lb-trans"><p>(908) 824-0775</p>
</div><p>ENRA@jtcir.com</p>
<div class="lb-trans"><p>ENRA@jtcir.com</p>
</div><p>A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/de652864-7d39-4b89-873f-72a4b65d76be</p>
<div class="lb-trans"><p>与此公告相关的照片可在 https://www.globenewswire.com/NewsRoom/AttachmentNg/de652864-7d39-4b89-873f-72a4b65d76be 获取</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVNU5EZzFNaU0zTXpBd05UQXdJekl5TVRBeU9EQT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTU5NDg1MiM3MzAwNTAwIzIyMTAyODA="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NTc5MGVkZjktOGQ1Yi00YzQwLWJhZGQtYzAzYWVlYzJmYWRhLTEyMjE4MzMtMjAyNS0xMi0wMi1lbg==/tiny/Ernexa-Therapeutics-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/NTc5MGVkZjktOGQ1Yi00YzQwLWJhZGQtYzAzYWVlYzJmYWRhLTEyMjE4MzMtMjAyNS0xMi0wMi1lbg==/tiny/Ernexa-Therapeutics-Inc-.png"/></p>

Ernexa Therapeutics Strengthens Scientific and Medical Advisory Board with Appointment of Leading Oncologist Dr. Ira S. Winer, M.D., Ph.D., FACOG | ERNA Stock News

Ernexa Therapeutics 通过任命著名肿瘤学家 Ira S. Winer 博士（医学博士，FACOG），加强了其科学和医学咨询委员会 | ERNA 股票新闻